POM-V Prescription Required Companion Animal

Buprecord 0.3 mg/ml Solution for Injection for Dogs and Cats

Active ingredient: Buprenorphine

Form

Injection

Species

Cats Dogs

Manufacturer

Labiana Life Sciences SA

VMD MA No.

32112/5001

What it's used for

Post-operative analgesia and sedation in the dog. Post-operative analgesia in the cat.

Full indications, dosage and side effects ↓

View official SPC (PDF)

The prescription itself has a price. See what practices near you charge for a consultation and the written prescription fee.

Paying less for Buprenorphine

1

Ask your vet for a written prescription

They must provide one on request. Under the CMA Order the fee is capped at £21 from 2027.
2

Fill it at a registered online retailer

The CMA found online pharmacies 50–60% cheaper than practice dispensing on common medicines — typically £200–£300 a year.

Your prescription rights → VMD register of retailers →

Prescription required

Your vet must provide a written prescription on request. You can then purchase from any licensed online retailer.

Clinical information

Buprecord 0.3 mg/ml Solution for Injection for Dogs and Cats — SPC Details

Source: VMD Summary of Product Characteristics (SPC). Last updated 27 Mar 2026.

Post-operative analgesia and sedation in the dog. Post-operative analgesia in
the cat.

(equivalent to 0.03-0.06 ml
of veterinary medicinal
product per kg of b.w.).
Repeat, if necessary, after
3-4
hours with 10 micrograms
of buprenorphine/ kg of
b.w. or after 5-6 hours with
20 micrograms of
buprenorphine per kg of
b.w.
10-20 micrograms of
buprenorphine/ kg of b.w.
(equivalent to 0.03-0.06
ml of veterinary
medicinal product per kg
of b-w.)
Cats
intramuscular
or intravenous
10 - 20 micrograms
buprenorphine/ kg of b.w.
(equivalent to 0.03-0.06 ml
of veterinary medicinal
product per kg of b.w.),
repeated, if necessary,
once, after 1-2 hours.
------
While sedative effects are present by 15 minutes after administration, analgesic activity
becomes apparent after approximately 30 minutes. To ensure that analgesia is present
during surgery and immediately on recovery, the product should be administered
preoperatively as part of premedication.
When administered for potentiation of sedation or as part of premedication, the dose
of other centrally-acting agents, such as acepromazine or medetomidine, should be
reduced. The reduction will depend on the degree of sedation required, the individual
animal, the type of other agents included in premedication and how anaesthesia is to
be induced and maintained. It may also be possible to reduce the amount of
inhalational anaesthetic used.
Animals administered opioids possessing sedative and analgesic properties may show
variable responses. Therefore, the response of individual animals should be
monitored, and subsequent doses should be adjusted accordingly. In some cases,
repeat doses may fail to provide additional analgesia. In these cases, consideration
should be given to using a suitable injectable NSAID.
An appropriately graduated syringe must be used to allow accurate dosing. The
stopper cannot be broached more than 44 times.

Do not administer by the intrathecal or peridural route.
Do not use pre-operatively for Caesarian section (see Section 3.7).
Do not use in cases of hypersensitivity to the active substance, or to any of the
excipients.

Dogs:
Uncommon
(1 to 10 animals / 1,000
animals treated):
Ptyalism, bradycardia, hypothermia, agitation,
dehydration and miosis.
Respiratory depression.
Rare
(1 to 10 animals / 10,000
animals treated):
Hypertension, tachycardia.
Sedation
Very rare
(<1 animal / 10,000 animals
treated, including isolated
reports):
Discomfort
, injection site pain.
1- Refer to section 3.5 Special precautions for safe use in the target species.
2- When used to provide analgesia, sedation may occur at dose levels higher
than those recommended.
3- Resulting in vocalisation.
4- Local
Cats:
Common
(1 to 10 animals / 100 animals
treated):
Mydriasis.
Behavioural disorders (restlessness, purring and
excessive rubbing).
Uncommon
(1 to 10 animals / 1,000
animals treated):
Respiratory depression.
Rare
(1 to 10 animals / 10,000
animals treated):
Sedation.
Very rare
(<1 animal / 10,000 animals
treated, including isolated
reports):
Discomfort
, injection site pain.
1- Refer to section 3.5 Special precautions for safe use in the target species.
2- When used to provide analgesia, sedation may occur at dose levels higher
than those recommended.
3- Resulting in vocalisation.
4- Will usually resolve within 24 hours.
5- Local
Reporting adverse events is important. It allows continuous safety monitoring of a
veterinary medicinal product.
Reports should be sent, preferably via a veterinarian, to either the marketing
authorisation holder or its local representative or the national competent authority via
the national reporting system. See the package leaflet for respective contact details.

None.

Special precautions for safe use in the target species:
Buprenorphine may cause respiratory depression and as with other opioid drugs, care
should be taken when treating animals with impaired respiratory function or animals
that are receiving drugs that can cause respiratory depression.
In case of renal, cardiac or hepatic dysfunction or shock, there may be greater risk
associated with the use of the product. The benefit/risk assessment for using the
product should be made by the attending vet. Safety has not been fully evaluated in
clinically compromised cats.
Buprenorphine should be used with caution in animals with impaired liver function,
especially biliary tract disease, as the substance is metabolised by the liver and its
intensity and duration of action may be affected in such animals.
The safety of buprenorphine has not been demonstrated in animals less than 7 weeks
of age, therefore, use in such animals should be based on the benefit/risk assessment
of the veterinarian.
Repeat administration earlier than the recommended repeat interval suggested in
Section 3.9 is not recommended.
Long-term safety of buprenorphine in cats has not been investigated beyond 5
consecutive days of administration.
The effect of an opioid on head injury is dependent on the type and severity of the
injury and the respiratory support supplied. The veterinary medicinal product should
be used in accordance with the benefit/risk assessment of the attending veterinarian.
Special precautions to be taken by the person administering the veterinary medicinal
product to animals:
The excipient chlorocresol can cause hypersensitivity (allergic) reactions after skin
contact. People with known hypersensitivity to chlorocresol should avoid contact with
the veterinary medicinal product. In case of accidental skin contact, wash off
immediately with water.
As buprenorphine has opioid activity, care should be taken to avoid self-injection or
ingestion. Buprenorphine may be absorbed systemically on exposure to mucous
membranes. The product, which is slightly acidic, may cause skin or eye irritation if
contact occurs. Following eye, skin or mouth contact, wash the affected area
thoroughly with water. Seek medical advice if irritation persists.
In case of accidental self-injection or ingestion, seek medical advice immediately and
show the package leaflet or the label to the physician. Wash hands after use.
To the physician: In case of accidental self-injection the opioid antagonist naloxone
may be used as antidote.
Special precautions for the protection of the environment:
Not applicable.

Buprenorphine may cause some drowsiness, which may be potentiated by other
centrally acting agents, including tranquillisers, sedatives and hypnotics.
There is evidence in humans to indicate that therapeutic doses of buprenorphine do
not reduce the analgesic efficacy of standard doses of an opioid agonist, and that when
buprenorphine is employed within the normal therapeutic range, standard doses of
opioid agonist may be administered before the effects of the former have ended without
compromising analgesia. However, it is recommended that
buprenorphine is not used in conjunction with morphine or other opioid-type
analgesics, e.g. etorphine, fentanyl, pethidine, methadone, papaveretum or
butorphanol.
Buprenorphine has been used with acepromazine, alphaxalone/alphadalone, atropine,
dexmedetomidine, halothane, isoflurane, ketamine, medetomidine, propofol,
sevoflurane, thiopentone and xylazine. When used in combination with sedatives,
depressive effects on heart rate and respiration may be augmented.

Keep the vial in the outer carton in order to protect from light.

Not applicable.
4.

This information is sourced from the official Summary of Product Characteristics (SPC) published by the Veterinary Medicines Directorate (VMD). It is provided for informational purposes only and does not replace professional veterinary advice. Always consult your vet before administering any medication.